P 2 Effect of ocrelizumab on humoral immunity markers in the phase iii, double-blind, double-dummy, IFN[formula omitted]-1a–controlled OPERA I and OPERA II studies

Autor: Ziemssen, T., Bar-Or, A., Arnold, D.L., Comi, G., Hartung, H.P., Hauser, S.L., Lublin, F., Selmaj, K., Traboulsee, A., Chin, P., Fontoura, P., Garren, H., Masterman, D., Kappos, L.
Zdroj: In Clinical Neurophysiology October 2017 128(10):e326-e327
Databáze: ScienceDirect
Externí odkaz: